Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD76m

    Last close

    USD0.81

    ▲ 0.14 (20.90%)

    Canyon Resources

    MCap

    AUD262m

    Last close

    AUD0.19

    ▲ 0.02 (12.12%)

    Immix Biopharma

    MCap

    USD51m

    Last close

    USD1.82

    ▲ 0.12 (7.06%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Executive interview with Carlos Buesa, CEO of Oryzon Genomics

Executive interview with Carlos Buesa, CEO of Oryzon Genomics

Oryzon Genomics — 4 videos in collection

More on this equity

Spanish biotech Oryzon Genomics is among the leading clinical-stage drug developers, with a second generation of epigenetic therapeutics that have greater selectivity and a potentially favourable safety/efficacy profile compared with the first-generation HDAC inhibitors. Oryzon is focused on epigenetics in oncology and the central nervous system (CNS). Iadademstat is being explored for acute leukaemias, small-cell lung cancer (SCLC) and neuroendocrine tumours. CNS asset vafidemstat has completed several Phase IIa trials and a Phase IIb trial in borderline personality disorder is now the lead study.

In this interview, Oryzon CEO Carlos Buesa recaps the company’s pipeline and provides a preview of the upcoming rich newsflow.

< Previous
Next >

You may also be interested in these:

Healthcare

Oryzon– Edison Open House interview

Healthcare

Executive interview – Oryzon

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free